Company intelligence / Profile preview
I-Mab
Rockville, Maryland, United Statesi-mabbiopharma.com ↗
- Ownership
- Public · IMAB
- Development stage
- Phase 1
01
Overview
I-Mab has completed Phase 3 trials for eftansomatropin alfa (TJ101) in pediatric growth hormone deficiency. Givastomig (CLDN18.2 x 4-1BB bispecific antibody) is in Phase 1b trials for gastric cancer with data expected in early second half of 2025. The company has recently prioritized givastomig as its lead clinical program.
- Therapeutic areas
- GastroenterologyOncologyEndocrinology
- Modalities
- Monoclonal antibodiesBispecific antibodiesRecombinant proteins
- Industry
- Biotech
02
Drug pipeline
18 assets17 more assets in the full pipeline.
Request access →03
Partnerships
04
Financials
- Market cap
- $542M
- Total revenue
- $0
- Enterprise value
- $379.9M
Beyond the preview
Go deeper on I-Mab.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on I-Mab.